Inventiva S.A. (EPA:IVA)
3.160
-0.060 (-1.86%)
Apr 24, 2025, 5:35 PM CET
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue
14.09M
Revenue Growth
-38.24%
P/S Ratio
21.45
Revenue / Employee
121.50K
Employees
118
Market Cap
302.29M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 44.29B |
Sartorius Stedim Biotech | 2.86B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.64B |
Inventiva News
- 9 days ago - Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F - GlobeNewsWire
- 23 days ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 4 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire
- 5 weeks ago - Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results - GlobeNewsWire
- 2 months ago - Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment - GlobeNewsWire
- 2 months ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 2 months ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire